Zulrahman Erlangga

Dr. Zulrahman Erlangga

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2019 in Hepatology Communications
Verified
Journal Article
Open access
PDF file
ASAnna Saborowski
Anna Saborowski
KWKatharina Wolff
Katharina Wolff
SSSteffi Spielberg
Steffi Spielberg
BBBenedikt Beer
Benedikt Beer
BHBjörn Hartleben
Björn Hartleben
MSMichael Saborowski
Michael Saborowski
The rising incidence of cholangiocarcinoma (CCA) coupled with a low 5‐year survival rate that remains below 10% delineates the urgent need for more effective treatment strategies. Although several recent studies provided detailed information on the genetic landscape of this fatal malignancy, versatile model systems to functionally dissect the immediate clinical relevance of the identified genetic alterations are still missing. To enhance our understanding of CCA pathophysiology and facilitate rapid functional annotation of putative CCA driver and tumor maintenance genes, we developed a tractable murine CCA model by combining the cyclization recombination (Cre)‐lox system, RNA interference, and clustered regularly interspaced short palindromic repeats/CRISPR associated protein 9 (CRISPR/Cas9) technology with liver organoids, followed by subsequent transplantation into immunocompetent, syngeneic mice. Histologically, resulting tumors displayed cytokeratin 19–positive ductal structures surrounded by a desmoplastic stroma—hallmark features of human CCAs. Despite their initial biliary phenotype in vitro, organoids retained the plasticity to induce a broader differentiation spectrum of primary liver cancers following transplantation into recipient mice, depending on their genetic context. Thus, the organoid system combines the advantage of using nontransformed, premalignant cells to recapitulate liver tumorigenesis as a multistep process, with the advantage of a reproducible and expandable cell culture system that abrogates the need for recurrent isolations of primary cells. Conclusion: Genetically modified liver organoids are able to transform into histologically accurate CCAs. Depending on the oncogenic context, they are also able to give rise to liver cancers that show features of hepatocellular carcinomas. The model can be used to functionally explore candidate cancer genes of primary liver cancers in immunocompetent animals and evaluate novel treatment regimens.

1 March 2023 in Human Nutrition & Metabolism
Verified
Journal Article
Open access
ZEZulrahman Erlangga
Zulrahman Erlangga
SGSamaneh Khosandam Ghashang
Samaneh Khosandam Ghashang
IHImad Hamdan
Imad Hamdan
AMAnette Melk
Anette Melk
CGChristoph Gutenbrunner
Christoph Gutenbrunner
BNBoya Nugraha
Boya Nugraha

21 April 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
UHUwe Hoff
Uwe Hoff
DMDenise Markmann
Denise Markmann
DTDaniela Thurn-Valassina
Daniela Thurn-Valassina
MNMelina Nieminen-Kelhä
Melina Nieminen-Kelhä
ZEZulrahman Erlangga
Zulrahman Erlangga
BHBjörn Hegner
Björn Hegner
Interstitial fibrosis and tubular atrophy, a major cause of kidney allograft dysfunction, has been linked to premature cellular senescence. The mTOR inhibitor Rapamycin protects from senescence in experimental models, but its antiproliferative properties have raised concern early after transplantation particularly at higher doses. Its effect on senescence has not been studied in kidney transplantation, yet. Rapamycin was applied to a rat kidney transplantation model (3 mg/kg bodyweight loading dose, 1.5 mg/kg bodyweight daily dose) for 7 days. Low Rapamycin trough levels (2.1–6.8 ng/mL) prevented the accumulation of p16INK4a positive cells in tubules, interstitium, and glomerula. Expression of the cytokines MCP-1, IL-1β, and TNF-α, defining the proinflammatory senescence-associated secretory phenotype, was abrogated. Infiltration with monocytes/macrophages and CD8+ T-lymphocytes was reduced and tubular function was preserved by Rapamycin. Inhibition of mTOR was not associated with impaired structural recovery, higher glucose levels, or weight loss. mTOR inhibition with low-dose Rapamycin in the immediate posttransplant period protected from premature cellular senescence without negative effects on structural and functional recovery from preservation/reperfusion damage, glucose homeostasis, and growth in a rat kidney transplantation model. Reduced senescence might maintain the renal regenerative capacity rendering resilience to future injuries resulting in protection from interstitial fibrosis and tubular atrophy.

29 November 2019 in Cancers
Verified
Journal Article
Open access
PDF file
ZEZulrahman Erlangga
Zulrahman Erlangga
KWKatharina Wolff
Katharina Wolff
TPTanja Poth
Tanja Poth
APAlexander Peltzer
Alexander Peltzer
SNSven Nahnsen
Sven Nahnsen
MSMichael Saborowski
Michael Saborowski
Gallbladder cancer is associated with a dismal prognosis, and accurate in vivo models will be elemental to improve our understanding of this deadly disease and develop better treatment options. We have generated a transplantation-based murine model for gallbladder cancer that histologically mimics the human disease, including the development of distant metastasis. Murine gallbladder–derived organoids are genetically modified by either retroviral transduction or transfection with CRISPR/Cas9 encoding plasmids, thereby allowing the rapid generation of complex cancer genotypes. We characterize the model in the presence of two of the most frequent oncogenic drivers—Kras and ERBB2—and provide evidence that the tumor histology is highly dependent on the driver oncogene. Further, we demonstrate the utility of the model for the preclinical assessment of novel therapeutic approaches by showing that liposomal Irinotecan (Nal-IRI) is retained in tumor cells and significantly prolongs the survival of gallbladder cancer–bearing mice compared to conventional irinotecan.

6 June 2019 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
AMAmrendra Mishra
Amrendra Mishra
FEFatemeh Emamgholi
Fatemeh Emamgholi
ZEZulrahman Erlangga
Zulrahman Erlangga
BHBjörn Hartleben
Björn Hartleben
KUKristian Unger
Kristian Unger
MSMichael Saborowski
Michael Saborowski
Beyond the nearly uniform presence of KRAS mutations, pancreatic cancer is increasingly recognized as a heterogeneous disease. Preclinical in vivo model systems exist, but with the advent of precision oncology, murine models with enhanced genetic flexibility are needed to functionally annotate genetic alterations found in the human malignancy. Here, we describe the generation of focal gene disruptions and large chromosomal deletions via inducible and pancreas-specific expression of Cas9 in adult mice. Experimental mice are derived on demand directly from genetically engineered embryonic stem cells, without the need for further intercrossing. To provide initial validation of our approach, we show that disruption of the E3 ubiquitin ligase Rnf43 accelerates Kras G12D-dependent tumourigenesis. Moreover, we demonstrate that this system can be used to rapidly interrogate the impact of complex cancer-associated alleles through the generation of a previously unstudied 1.2 megabase deletion surrounding the CDKN2A and CDKN2B tumour suppressors. Thus, our approach is capable of reproducibly generating biallelic and precise loss of large chromosomal fragments that, in conjunction with mutant Kras, leads to development of pancreatic ductal adenocarcinoma with full penetrance.

1 July 2019 in European Journal of Physical and Rehabilitation Medicine
Verified
Journal Article
Closed access
SASumadi L. Anwar
Sumadi L. Anwar
GAGuritno Adistyawan
Guritno Adistyawan
WWWahyu Wulaningsih
Wahyu Wulaningsih
ZEZulrahman Erlangga
Zulrahman Erlangga
CGChristoph Gutenbrunner
Christoph Gutenbrunner
BNBoya Nugraha
Boya Nugraha